ClinicalTrials.gg
RecruitingNCT05917106Updated Nov 17, 2026

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

An observational study in Carcinoma, Renal Cell Carcinoma and RCC, sponsored by Jinling Hospital, China. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionCarcinoma, Renal CellRegistry: CarcinomaReclassifiedWhy we changed it
Registry
Carcinoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Renal Cell
Why
  1. The study's listed conditions name Carcinoma, Renal Cell, a narrower term within Carcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jinling Hospital, China · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Planned enrollment
16th of 45
450 · median 300
Started
2022
with 21 others
Observational
45 of 235
25 open now
Primary completion
2028-06
later than 116 of 141 live
Registered
115th of 235
by date
Lead sponsor
9 of 235
Jinling Hospital, China

Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 16th largest by planned enrollment of the 45 observational ones that give a count, is one of 22 that started in 2022, is one of 45 observational ones, reaches primary completion later than 116 of the 141 other live ones, and was the 115th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Read the detailed description

Some studies have shown the potential of ctDNA in renal cancer monitoring, but the amount of ctDNA released in renal cancer is the lowest among non-cranial tumors. Even in advanced patients, the detection rate of tumor system mutation is less than 50%. DNA methylation is important in the process of tumor occurrence and development. However, no studies have focused on the value of ctDNA methylation in monitoring renal cancer, nor have large prospective cohort studies been conducted in patients with renal cancer.

This study intended to analyze the dynamic changes of circulating tumor DNA and its methylation status in patients with kidney cancer from preoperative to long-term follow-up, and to compare the evaluation value of methylation detection with traditional imaging examination and traditional blood tumor markers in the monitoring process.

03

Conditions studied

  • Carcinoma
  • Renal Cell Carcinoma
  • RCC
  • Kidney Neoplasms
  • Kidney Cancer

Browse trials for

04

In context

Carcinoma, Renal Cell Reclassified

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

This study's planned enrollment of 450 is above the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Jinling Hospital, China is the lead sponsor of 131 studies on the registry; 35 are open to participants now.

Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

RCC patients undergoing surgical treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed renal cell carcinoma
  • Without any treatment
  • Agree and accept radical surgical treatment
  • Signed written
  • (Eastern Cooperative Oncology Group) performance is 0 or 1
  • Follow up protocol and related procedures

Exclusion criteria

Exclusion Criteria:

  • Had other cancers
  • Had received any antitumor therapy before
  • Known or suspected active disease
  • is not possible due to medical or psychiatric problems
  • Have clinical symptoms or diseases of the heart that are not well controlled
  • Patients judged by the investigators to be unsuitable for inclusion in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. To explore the predictive effect of ctDNA methylomics on the prognosis and medication guidance of renal carcinoma.

    Time frame: 5 years

  2. To explore the advance time of ctDNA methylomics in monitoring postoperative recurrence of renal cancer compared with imaging.

    Time frame: 5 years

  3. The molecular mechanism of renal cancer recurrence was analyzed with baseline tissue and circulating methylation profiles.

    Time frame: 5 years

  4. A renal cancer recurrence risk model was established based on clinical information, molecular risk factors and ctDNA methylomics

    Time frame: 5 years

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jun 2028, 66 months after the start.

Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's planned 66 months is above that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jun 23, 2023
StartActual
Dec 26, 2022
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05917106
Responsible party
Le Qu (Associate chief urologist, Jinling Hospital, China) — Principal investigator
First posted
Jun 23, 2023
Start date
Dec 26, 2022
Primary completion
Jun 2028 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Le Qe, M.D.
Contact
septsoul@hotmail.com
15720625951

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion